Fiduciary Financial Group LLC Has $302,000 Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Fiduciary Financial Group LLC cut its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,432 shares of the specialty pharmaceutical company’s stock after selling 142 shares during the period. Fiduciary Financial Group LLC’s holdings in Jazz Pharmaceuticals were worth $302,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of JAZZ. Choreo LLC increased its position in shares of Jazz Pharmaceuticals by 58.2% during the fourth quarter. Choreo LLC now owns 2,954 shares of the specialty pharmaceutical company’s stock worth $363,000 after acquiring an additional 1,087 shares in the last quarter. Bleakley Financial Group LLC grew its position in Jazz Pharmaceuticals by 52.5% in the fourth quarter. Bleakley Financial Group LLC now owns 3,112 shares of the specialty pharmaceutical company’s stock valued at $383,000 after purchasing an additional 1,071 shares in the last quarter. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at $464,000. Savant Capital LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at $272,000. Finally, Summit Trail Advisors LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at $539,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan acquired 100,000 shares of the stock in a transaction on Friday, May 9th. The stock was acquired at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the transaction, the director now owns 100,000 shares of the company’s stock, valued at $9,826,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer now directly owns 439,307 shares of the company’s stock, valued at approximately $51,113,369.45. This trade represents a 0.23% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,000 shares of company stock worth $355,925. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $113.00 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $6.97 billion, a PE ratio of 15.92, a P/E/G ratio of 1.04 and a beta of 0.33. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a 50-day moving average price of $107.65 and a two-hundred day moving average price of $120.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to analysts’ expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company’s quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.68 earnings per share. Equities analysts forecast that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price objective for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Robert W. Baird decreased their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Barclays reissued an “overweight” rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Finally, Piper Sandler restated an “overweight” rating and set a $147.00 target price (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.